Journal of Cancer
ISSN: 1837-9664
3.2
Impact Factor
ISSN: 1837-9664
Global reach, higher impact
J Cancer 2011; 2:324-328. doi:10.7150/jca.2.324 This volume Cite
Short Report
Targeting EGFR in Triple Negative Breast Cancer
1. Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
2. Department of Breast Medical Oncology, Morgan Welch Inflammatory Breast Cancer Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Citation:
Ueno NT, Zhang D. Targeting EGFR in Triple Negative Breast Cancer. J Cancer 2011; 2:324-328. doi:10.7150/jca.2.324. https://www.jcancer.org/v02p0324.htm
Other stylesAbstract
Our preliminary data show that erlotinib inhibits Triple-negative breast cancer (TNBC) in a xenograft model. However, inhibition of metastasis by erlotinib is accompanied by nonspecific effects because erlotinib can inhibit other kinases; thus, more direct targets that regulate TNBC metastasis need to be identified to improve its therapeutic efficacy.
Keywords: triple negative breast cancer, tyrosine kinase inhibitor, EGFR, erlotinib, metastasis
Citation styles
APA
Ueno, N.T., Zhang, D. (2011). Targeting EGFR in Triple Negative Breast Cancer. Journal of Cancer, 2, 324-328. https://doi.org/10.7150/jca.2.324.
ACS
Ueno, N.T.; Zhang, D. Targeting EGFR in Triple Negative Breast Cancer. J. Cancer 2011, 2, 324-328. DOI: 10.7150/jca.2.324.
NLM
Ueno NT, Zhang D. Targeting EGFR in Triple Negative Breast Cancer. J Cancer 2011; 2:324-328. doi:10.7150/jca.2.324. https://www.jcancer.org/v02p0324.htm
CSE
Ueno NT, Zhang D. 2011. Targeting EGFR in Triple Negative Breast Cancer. J Cancer. 2:324-328.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.